TruScreen Board Appointment

NZX Announcement
2 March 2021
TruScreen Board Appointment
• Fisher & Paykel Healthcare’s Dr Dexter Cheung joins as
Non-Executive Director
• Mr Chris Lawrence retires

Truscreen Group Limited (NZX and ASX:TRU) (TruScreen or Company) is pleased to announce the
appointment of Dr. Dexter Cheung as a non-executive director of TruScreen.
Dr. Cheung is an experienced medical device engineer and specialist in product research and development,
with more than 20 years’ experience. He is the Research & Development Manager of the respiratory
humidification division of Fisher & Paykel Healthcare, an NZX/ASX listed healthcare company and a global
leader in respiratory medical devices.
Dr Cheung’s technical background in opto-electronics and expertise in medical device engineering is highly
relevant to TruScreen whose cervical cancer screening device harnesses optical and electrical signatures for
screening results.
Dr Cheung brings a strong understanding of manufacturing processes and has travelled extensively to China,
USA, Europe, United Kingdom and Japan working closely with medical device manufacturers and component
suppliers in these regions.
Dr Cheung has published eight papers and has eight international patents pending or granted jointly with
collaborators or in his name, focusing on respiratory air flow management. He has previously served on a
visiting committee of the Auckland University of Technology.
Dr. Cheung holds a first-class honours degree in Bachelor of Technology, a Master of Engineering (first class
honours) degree and a Doctor of Philosophy (in physics) from his alma mater, University of Auckland.
Mr. Chris Lawrence has also announced his retirement from the board due to health reasons. Shareholders
would recall that Mr. Lawrence was unable to attend the last annual shareholders general meeting in August
2020 for health reasons.
Tony Ho, Chairman commented “On behalf of the board, I thank Chris Lawrence for his unstinting contributions
to the board over the past four years.
“The directors are pleased to welcome Dr. Dexter Cheung to the Board of TruScreen. He brings very relevant
technical and product development experience with a major global healthcare firm, along with the business
experience and manufacturing expertise within our key markets of China and Central America. This skill set will
assist TruScreen as we continue to evolve and scale up.

This release to NZX/ASX has been authorised by the Board.

-ENDS-

For more information visit www.TruScreen.com or contact:

TruScreen
Tony Ho
Chairman
tonyho@truscreen.com

TruScreen
Juliet Hull
CEO
juliethull@truscreen.com
Investor Relations
Trevor Chappell

Tchappel@we-worldwide.com


About TruScreen:
TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-
time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being
of women around the world.
TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the
cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.
TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with
conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for
supporting laboratory infrastructure. As such, TruScreen’s target market is low and middle-income countries
where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico,
Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for use
throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is
significant.